Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Bifidobacterium Quadruple Live Bacteria Tablets (Si Lian Kang) Reducing the Incidence Rate of Adverse Reactions in Helicobacter Pylori Quadruple Eradication Therapy and on the Effects of Gastrointestinal Flora

NCT04034641 is registered in ClinicalTrials.gov with Hangzhou Grand Biologic Pharmaceutical, Inc. as lead sponsor.

NCT NCT04034641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04034641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Bifidobacterium Quadruple Live Bacteria Tablets (Si Lian Kang) Reducing the Incidence Rate of Adverse Reactions in Helicobacter Pylori Quadruple Eradication Therapy and on the Effects of Gastrointestinal Flora
Lead sponsor
Hangzhou Grand Biologic Pharmaceutical, Inc.
Phase
Phase 4
Overall status
Unknown status
Start date
June 17, 2019
Completion date
December 31, 2021
Enrollment
238 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori eradication